Tiny OncoSec Surges on Promising Phase II Melanoma Data Post author:Sam Post published:November 7, 2017 Post category:BioPharma The updated data will be presented at the 2017 Society for Immunotherapy of Cancer Annual Meeting. Source: BioSpace You Might Also Like Caris Life Sciences' Molecular Intelligence Platform Identifies Patients With MSI-High (Or Mismatch Repair Deficient) Solid Tumors More Likely To Respond To Immunotherapy June 8, 2017 AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer May 7, 2017 Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks October 10, 2017
Caris Life Sciences' Molecular Intelligence Platform Identifies Patients With MSI-High (Or Mismatch Repair Deficient) Solid Tumors More Likely To Respond To Immunotherapy June 8, 2017
AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer May 7, 2017